Teyi Pharmaceutical Group Co.,Ltd (002728.SZ)
- Previous Close
9.52 - Open
10.01 - Bid 9.52 x --
- Ask 9.53 x --
- Day's Range
9.40 - 9.57 - 52 Week Range
8.25 - 17.49 - Volume
8,031,051 - Avg. Volume
24,286,508 - Market Cap (intraday)
4.866B - Beta (5Y Monthly) 1.58
- PE Ratio (TTM)
28.03 - EPS (TTM)
0.34 - Earnings Date --
- Forward Dividend & Yield 0.50 (5.25%)
- Ex-Dividend Date Apr 24, 2024
- 1y Target Est
13.93
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of proprietary Chinese medicines, chemical preparations, raw materials, and products in the People's Republic of China. The company offers cough and phlegm, kidney, anti- infection, cardiovascular and cerebrovascular, and digestive system drugs. Its chemical raw materials and products include aluminum magnesium carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceutical Group Co.,Ltd in November 2016. Teyi Pharmaceutical Group Co.,Ltd was founded in 2002 and is based in Taishan, the People's Republic of China.
www.tczy.com.cn--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002728.SZ
Performance Overview: 002728.SZ
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002728.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002728.SZ
Valuation Measures
Market Cap
4.87B
Enterprise Value
4.58B
Trailing P/E
28.39
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.68
Price/Book (mrq)
2.41
Enterprise Value/Revenue
4.93
Enterprise Value/EBITDA
23.98
Financial Highlights
Profitability and Income Statement
Profit Margin
16.91%
Return on Assets (ttm)
4.69%
Return on Equity (ttm)
8.89%
Revenue (ttm)
927.67M
Net Income Avi to Common (ttm)
156.86M
Diluted EPS (ttm)
0.34
Balance Sheet and Cash Flow
Total Cash (mrq)
585.6M
Total Debt/Equity (mrq)
14.65%
Levered Free Cash Flow (ttm)
-61.2M
Research Analysis: 002728.SZ
Company Insights: 002728.SZ
002728.SZ does not have Company Insights